Categories
OPS lanza nuevo tablero interactivo para monitorear virus respiratorios en las Américas
PAHO launches new interactive dashboard to monitor respiratory viruses in the Americas
Cristina Mitchell
8 Jul 2025
Categories
Measles cases rise in the Americas in 2025
Measles cases rise in the Americas in 2025
Cristina Mitchell
3 Jul 2025
Categories
PAHO and CDRI Sign Agreement to Strengthen Health Infrastructure Resilience Against Disasters
PAHO and CDRI Sign Agreement to Strengthen Health Infrastructure Resilience Against Disasters
Cristina Mitchell
3 Jul 2025
Categories
WHO launches bold push to raise health taxes and save millions of lives
WHO launches bold push to raise health taxes and save millions of lives
Cristina Mitchell
2 Jul 2025
Categories
PAHO and Global Affairs Canada initiative strengthens the health of women and adolescents in situations of vulnerability in six countries of the Americas
PAHO and Global Affairs Canada initiative strengthens the health of women and adolescents in situations of vulnerability in six countries of the Americas
Cristina Mitchell
2 Jul 2025
Categories
Noncommunicable disease deaths in the Americas have risen 43% since 2000, PAHO report shows
Noncommunicable disease deaths in the Americas have risen 43% since 2000, PAHO report shows
Cristina Mitchell
2 Jul 2025
Categories
Cybersecurity Vulnerabilities with Certain Patient Monitors from Contec and Epsimed: FDA Safety Communication
The FDA is raising awareness about cybersecurity vulnerabilities with Contec CMS8000 and Epsimed MN-120 patient monitors.
Categories
Early Alert: Infusion Pump Software Issue from Baxter
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Categories
Early Alert: Blood Pump Controller Issue from Abiomed
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Categories
Extended-Release Stimulants for ADHD: FDA Drug Safety Communication – FDA Requires Expanded Labeling about Weight Loss Risk in Patients Younger than 6 Years
The FDA is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) – including certain formulations of amphetamine and methylphenidate – to warn about the risk of weight loss and other adverse reactions (side effects) in patients yo
